These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30636227)

  • 1. Compliance with the RSV immunoprophylaxis dosing schedule in the Polish registry for palivizumab (2008-2014).
    Borecka R; Lauterbach R
    Dev Period Med; 2018; 22(4):308-314. PubMed ID: 30636227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland.
    Borecka R; Lauterbach R; Helwich E
    Dev Period Med; 2016; 20(3):181-190. PubMed ID: 27941187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
    Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
    Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
    Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
    Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
    Lundeen K; Pfeiffenberger T; Jacobson Vann J; O'Brien T; Sampson C; Wegner S
    J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
    Claydon J; Sur A; Callejas A; Ladd M; Kwan E; Taylor R; Turvey SE; Solimano A; Lavoie PM; Marr N
    PLoS One; 2017; 12(4):e0176152. PubMed ID: 28437470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD007743. PubMed ID: 27439110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
    Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
    Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida.
    Hampp C; Saidi AS; Winterstein AG
    J Pediatr; 2010 Jun; 156(6):953-959.e1. PubMed ID: 20223478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting.
    Golombek SG; Berning F; Lagamma EF
    Pediatr Infect Dis J; 2004 Apr; 23(4):318-22. PubMed ID: 15071285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.
    de Souza RP; Ribeiro ALR; de Menezes SAF; Machado LFA
    BMC Pediatr; 2019 Aug; 19(1):299. PubMed ID: 31462289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A post-incorporation study on the use of palivizumab in the Brazilian public health system.
    Batista JDL; Ferreira MAP; Xavier CDS; Souza ITA; Cruz LN; Polanczyk CA
    Rev Inst Med Trop Sao Paulo; 2021; 63():e5. PubMed ID: 33533808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants].
    Bernard L; Lecomte B; Pereira B; Proux A; Boyer A; Sautou V
    Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory syncytial virus (RSV) infection in children with medical complexity.
    Lim A; Butt ML; Dix J; Elliott L; Paes B
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.